Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 2, 2014, Pages 220-228

  Shi, Chanjuan ^a   Merchant, Nipun ^b   Newsome, Guy ^c   Goldenberg, David M ^c   Gold, David V ^c  

^a Departments of Pathology Microbiology and Immunology ^*  (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUC1 PROTEIN, HUMAN; MUCIN 1; PAM4 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER STAGING; CHRONIC PANCREATITIS; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; PANCREAS; PANCREAS CARCINOMA; PANCREAS CYST; PANCREAS DUCT; PANCREAS RESECTION; PANCREAS TUMOR; PATHOLOGY; PRECANCER; TISSUE MICROARRAY;

ANTIGENS, NEOPLASM; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MUCIN-1; NEOPLASM GRADING; NEOPLASM STAGING; PANCREAS; PANCREATECTOMY; PANCREATIC CYST; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PRECANCEROUS CONDITIONS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893694967     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0056-OA     Document Type: Article

References (46)

1. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131(4):247-255.
2. Harinck F, Poley JW, Kluijt I, Fockens P, Bruno MJ. Is early diagnosis of pancreatic cancer fiction?: surveillance of individuals at high risk for pancreatic cancer. Dig Dis. 2010;28(4-5):670-678.
3. Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. Adv Surg. 2010;44(10):293-311.
4. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993;328(20):1433-1437.
5. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol. 2010;24(3):349-358.
6. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129(2):504-511.
7. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10(1):88-95.
8. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142(4): 796-804.
9. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut. 2009; 58(10):1410-1418.
10. Gold DV, Gaedcke J, Ghadimi BM, et al. Detection of early-stage pancreatic ductal adenocarcinoma (PDAC): sensitivity, specificity, and discriminatory properties of the serum-based PAM4-immunoassay. Cancer. 2013;119(3): 522-528.
11. Gold DV, Goggins M, Modrak DE, et al. Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2010;19(11): 2786-2794.
12. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res. 2007;13(24):7380-7387.
13. Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer. 1994;57(2):204-210.
14. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol. 2006;24(2):252-258.
15. Ishida M, Major PP, Ura Y, Dion AS. Related glycoproteins from normal secretory and malignant breast cells. Purification and initial comparative characterizations. Tumor Biol. 1989;10(1):12-24.
16. Moniaux N, Varshney GC, Chauhan SC, et al. Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J Histochem Cytochem. 2004;52(2):253-261.
17. Shi C, Hong SM, Lim P, et al. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Mol Cancer Res. 2009;7:230-236.
18. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
19. Oto A, Eltorky MA, Dave A, et al. Mimicks of pancreatic malignancy in patients with chronic pancreatitis: correlation of computed tomography imaging features with histopathologic findings. Curr Probl Diagn Radiol. 2006;35(5):199-205.
20. Taylor, B. Carcinoma of the head of the pancreas versus chronic pancreatitis: diagnostic dilemma with significant consequences. World J Surg. 2003;27(11):1249-1257.
21. Hernandez JM, Cowgill SM, Al-Saadi S, et al. CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg. 2009;13(2):349-353.
22. Itzkowitz SH, Yuan M, Fukushi Y, et al. Immunohistochemical comparison of Lea, monosialosyl Lea (CA 19-9), and disialosyl Lea antigens in human colorectal and pancreatic tissues. Cancer Res. 1988;48(13):3834-3842.
23. Park HU, Kim JW, Kim GE, et al. Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas. 2003;26(3):e48-e54.
24. Andrianifahanana M, Moniaux N, Schmied BM, et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res. 2001;7(12):4033-4040.
25. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7(12):3862-3868.
26. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266-270.
27. Habbe N, Koorstra JB, Mendell JT, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther. 2009;8(4):340-346.
28. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003;63(24):8614-8622.
29. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12(2):442-446.
30. Adsay NV, Merati K, Andea A, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol. 2002;15(10):1087-1095.
31. Kim GE, Bae HI, Park HU, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology. 2002;123(4):1052-1060.
32. Swartz MJ, Batra SK, Varshney GC, et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol. 2002; 117(5):791-796.
33. Bhardwaj A, Marsh WL Jr, Nash JW, Barbacioru CC, Jones S, Frankel WL. Double immunohistochemical staining with MUC4/p53 is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray-based study. Arch Pathol Lab Med. 2007;131(4):556-562.
34. Liu H, Shi J, Anandan V, et al. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas. Arch Pathol Lab Med. 2012;136(6):601-609.
35. Westgaard A, Schjlberg AR, Cvancarova M. Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology. 2009;54(3): 337-347.
36. Jhala N, Jhala D, Vickers SM, et al. Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol. 2006;126(4):572-579.
37. Saitou M, Goto M, Horinouchi M, et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol. 2005;58(8):845-852.
38. Brugge WR. The incidental pancreatic cyst on abdominal computerized tomography imaging: diagnosis and management. Clin Gastroenterol Hepatol. 2008;6(2):140-144.
39. Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126(5):1330-1336.
40. Fernández-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg. 2003;138(4):427-423.
41. Hong SM, Park JY, Hruban RH, Goggins, M. Molecular signatures of pancreatic cancer. Arch Pathol Lab Med. 2011;135(6):716-727.
42. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28(8):977-987.
43. Katz DS, Friedel DM, Kho D, Georgiou N, Hines JJ. Relative accuracy of CT and MRI for characterization of cystic pancreatic masses. Am J Roentgenol. 2007; 189(3):657-661.
44. Toll AD, Kowalski T, Loren D, Bibbo M. The added value of molecular testing in small pancreatic cysts. JOP. 2010;11(6):582-586.
45. Mertz H. K-ras mutations correlate with atypical cytology and elevated CEA levels in pancreatic cystic neoplasms. Dig Dis Sci. 2011(7);56:2197-2201.
46. Kern S, Hruban R, Hollingsworth MA, et al. A white paper: the product of a pancreas cancer think tank. Cancer Res. 2001;61(12):4923-4932.